Mr. Hugh MacNaught reports

VENTRIPOINT ISSUES OPTION GRANTS AND REPORTS EXERCISE OF OPTIONS

Ventripoint Diagnostics Ltd., on Sept. 6, 2024, granted an aggregate of 2,917,000 options to directors, officers, employees, contractors and consultants of the corporation, with an exercise price of between 17.5 cents and 20 cents, and terms of one to 10 years. All options vested immediately. Of these option grants, 200,000 were awarded to directors and an additional 375,000 were awarded to officers, some of whom were also directors of the corporation, at an exercise price of 20 cents, and 250,000 options were awarded to a consultant of the corporation, with an exercise price of 20 cents and with a term of one year.

Option grants are an important part of incentivizing stakeholders to drive value in the corporation, and the corporation has not awarded its directors, officers, employees or contractors option grants for 18 months.

Since the last update (see news release dated May 17, 2023), a total of 1,342,500 options were exercised with a weighted average price of approximately 10 cents per share for gross proceeds to the corporation of $136,000. There are currently 11,132,000 option grants outstanding, with exercise prices between 10 cents and 50 cents, with a weighted average price of 25 cents, and 9,372,833 of these options have vested.

The corporation has 4,200,391 options available for future grants under the stock option plan as approved by shareholders at the last special and annual general meeting of the corporation on Nov. 1, 2023.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide its future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.